JSW
IRWD icon

Journey Strategic Wealth’s Ironwood Pharmaceuticals IRWD Stock Holding History

Journey Strategic Wealth’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,155
Closed -$45K – 525
2024
Q4 		$45K Buy
+10,155
New +$41.2K ﹤0.01% 498

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Journey Strategic Wealth's IRWD Position: Q1 2025 in Review

Journey Strategic Wealth sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 10,155 shares — an estimated $45K sold.

Journey Strategic Wealth first reported a position in IRWD in Q4 2024 and held it in 1 quarter. The position peaked at $45K in Q4 2024. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Journey Strategic Wealth reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Journey Strategic Wealth sold 10,155 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $45K.
  • Journey Strategic Wealth first reported a position in Ironwood Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Journey Strategic Wealth's Ironwood Pharmaceuticals position peaked at $45K in Q4 2024.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Journey Strategic Wealth's 13F filing for Q1 2025, filed 6 May 2025.